Research Topics
| Chau DangSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directionsChau T Dang
Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Expert Rev Anticancer Ther 6:427-36. 2006..Newer agents are on the horizon...- Potential role of selective COX-2 inhibitors in cancer managementChau T Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Oncology (Williston Park) 16:30-6. 2002..Clinical trials using targeted inhibitors of COX-2 will be critical in determining if COX-2 is a viable molecular target in cancer management... - Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the icebergChau Dang
Department of Medicine, Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Breast Cancer 7:51-8. 2006..Thus, taxanes should be incorporated into the adjuvant treatment of breast cancer. To date, the available data do not allow one to select a single best taxane, schedule, or overall regimen... - The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancerChau Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 713, New York, NY 10021, USA
J Clin Oncol 26:1216-22. 2008..The primary end point was cardiac safety, and the secondary end points were time to recurrence and overall survival... - Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasibleChau Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Breast Cancer 8:418-24. 2008..Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility... - Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 10:5754-61. 2004..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival... - Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrheaChau Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 28:2982-8. 2010..We conducted a pilot study of dose-dense AC followed by PT plus lapatinib (PTL) followed by trastuzumab plus lapatinib (TL)... - Risk models for neutropenia in patients with breast cancerChau T Dang
Breast Cancer Medical Service, Memorial Sloan Kettering, Cancer Center, New York, New York, USA
Oncology (Williston Park) 17:14-20. 2003..These findings could lead to changes in how early-stage breast cancer is managed... - Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal studyArti Hurria
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Am Geriatr Soc 54:925-31. 2006..To report on the longitudinal cognitive functioning of older women receiving adjuvant chemotherapy for breast cancer... - A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
Clin Cancer Res 17:3398-407. 2011..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) ? nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer... - A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapyArti Hurria
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Am Geriatr Soc 54:1119-24. 2006..To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL)... - Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancerAyca Gucalp
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Clin Breast Cancer 11:306-11. 2011..We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC)... - Current status of the taxanes as adjuvant therapy for breast cancerClifford Hudis
Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, MSKCC, 1275 York Avenue, New York, NY, USA
Breast 16:S132-5. 2007..These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research... - Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspectiveArti Hurria
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Breast Cancer Res Treat 98:343-8. 2006..This longitudinal prospective study describes the older breast cancer patient's perception of the cognitive impact of adjuvant chemotherapy... - Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancerTiffany A Traina
Breast Cancer Medicine Service, Departments of Radiology, Biostatistics, and Renal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 28:628-33. 2010..We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)... - Adjuvant taxanes: more to the storyDevika Gajria
Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Clin Breast Cancer 10:S41-9. 2010..In this overview, we will review some of the key trials that have advanced the standard of care in the adjuvant setting with regard to various chemotherapy combinations... - Cardiac dysfunction associated with trastuzumabKaren Lisa Smith
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Expert Opin Drug Saf 5:619-29. 2006..This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity... - Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 10:4062-7. 2004..CONCLUSIONS: Celecoxib combined with trastuzumab is well tolerated. However, this combination in patients with HER2/neu-overexpressing, trastuzumab-refractory disease, was not active... - A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerMaura N Dickler
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 14:7878-83. 2008..To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway... - Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative groupClifford A Hudis
Breast Dis 21:3-13. 2004 - Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fractionPatrick G Morris
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 27:6117-23. 2009..Dose-dense (dd) AC followed by paclitaxel (P) is superior to the same regimen given every third week. Herein, we report the early cardiac safety of three sequential studies of ddAC alone or with bevacizumab (B)... - The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinomaRose Lai
Department of Epidemiology and Biostatistics, McMaster University/Hamilton Regional Cancer Center, Hamilton, Ontario, Canada
Cancer 101:810-6. 2004..056). CONCLUSIONS: Despite the impression of many oncologists, the results of this study did not support an association between trastuzumab therapy and an increased risk of CNS metastases...